Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
PKC delta and epsilon in drug targeting and therapeutics. | 2009 |
|
The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (εPKC)-versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design. | 2013 Apr |
|
A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. | 2013 Jun |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
124037376
Created by
admin on Sat Dec 16 10:10:58 GMT 2023 , Edited by admin on Sat Dec 16 10:10:58 GMT 2023
|
PRIMARY | |||
|
1253964-58-7
Created by
admin on Sat Dec 16 10:10:58 GMT 2023 , Edited by admin on Sat Dec 16 10:10:58 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
KAI-1678
Created by
admin on Sat Dec 16 10:10:58 GMT 2023 , Edited by admin on Sat Dec 16 10:10:58 GMT 2023
|
PRIMARY | Official Title: A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia, Purpose: The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain, Primary Outcome Measures: The effect of KAI-1678 on mean change from baseline in pain intensity at 6 hours (PID 6). (Time Frame: Day 1) (Designated as safety issue: No) Measurements are made using a qualified pain scale and the change from basline is calculated at 6 hours. | ||
|
1041004-14-1
Created by
admin on Sat Dec 16 10:10:58 GMT 2023 , Edited by admin on Sat Dec 16 10:10:58 GMT 2023
|
PRIMARY | |||
|
32P8I5VL5A
Created by
admin on Sat Dec 16 10:10:58 GMT 2023 , Edited by admin on Sat Dec 16 10:10:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY